European Commission Approves ORSERDU® for ER+ Breast Cancer with ESR1 Mutation

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...

September 14, 2023 | Thursday | News
BostonGene and Hokkaido University Hospital Collaborate to Develop Novel HER2 Protocols for Breast Cancer

Located in Sapporo, Japan, Hokkaido University Hospital stands as one of the most prominent medical institutions in the country. Affiliated with Hokkaido U...

September 20, 2023 | Wednesday | News
AHF Slams Johnson & Johnson for Immoral Profiteering on TB Treatment

“While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics ...

September 20, 2023 | Wednesday | News
NTT and NCNP to Collaborate in Japan to Develop Brain Bio-Digital Twin Technology

News Highlights: Brain Bio-Digital Twin technology has the potential to change medical treatment practices by eliminating the need for invasive and cost...

September 15, 2023 | Friday | News
SomaLogic Identifies Key Proteins for Early Cancer Detection

SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types. In a new paper published in Nature's Scientific Repo...

September 13, 2023 | Wednesday | News
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China

Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile--   Clover Biopharmaceutica...

September 12, 2023 | Tuesday | News
WELL Health and Orion Health Forge Global Partnership for Public Health Integration

Orion Health is a leading open healthcare platform provider committed to unifying data across complex health systems serving 12 count...

September 11, 2023 | Monday | News
Bristol Myers Squibb's LPA1 Antagonist Slows Lung Decline in Pulmonary Fibrosis Study

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predict...

September 11, 2023 | Monday | News
Gilead's Phase 2 Study Shows Promise for Trodelvy and KEYTRUDA in First-Line Lung Cancer

– Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studie...

September 11, 2023 | Monday | News
Mindray Introduces Groundbreaking 2-in-1 Handheld Ultrasound Device with Multi-device Connectivity

Mindray, a global leader and developer of healthcare solutions and technologies in ultrasound, patient monitoring, and anesthesia, anno...

September 08, 2023 | Friday | News
Clearmind Medicine Collaborates with Johns Hopkins to Study CMND-100 for Alcohol Use Disorder

The principal investigator, Jennifer Ellis, PhD, Associate Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine will be supported by co-...

September 07, 2023 | Thursday | News
Neurophet becomes the inaugural Korean firm selected by Roche Diagnostics for the Startup Creasphere APAC Program

Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the global startup innovation program 'Startu...

September 06, 2023 | Wednesday | News
MedAlliance Enrolls First Patient in SELUTION SLR LOVE-DEB Coronary Study

The aim of the LOVE-DEB Study (Large de-NOVo coronary artEry disease treated with sirolimus Drug Eluting Balloon: prospective evaluation of safety & ef...

September 06, 2023 | Wednesday | News
Zimmer Biomet India Launches Zimmer Biomet on Wheels Campaign

To launch the initiative Mandira Bedi, an actress, television presenter and a health & fitness icon, joined Zimmer Biomet Asia Pacific Group President ...

September 06, 2023 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in